Global Blood Therapeutics Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Global Blood Therapeutics's estimated annual revenue is currently $24M per year.
- Global Blood Therapeutics received $115.0M in venture funding in December 2017.
- Global Blood Therapeutics's estimated revenue per employee is $82,560
- Global Blood Therapeutics has 291 Employees.
- Global Blood Therapeutics grew their employee count by 60% last year.
- Global Blood Therapeutics currently has 28 job openings.
|Martine Kraus||Vice President, Regulatory Affairs|
|Gwendolyn Whitney||VP, US Commercial Operations|
|Ted Love||President & CEO|
|Hing Sham||Senior Vice President at Global Blood Therapeutics|
|Xiang Wang||Associate Director|
|Sarah Thayer||Executive Director, Clinical Operations at Global Blood Therapeutics|
|Margaret Tonda||Senior Director|
|Ze Cong||Senior Director, Health Economics and Outcomes Research|
|Mabel Chau||Director, Program Management|
|David Gao||Senior Director, CMC Analytical|
What Is Global Blood Therapeutics?
Global Blood Therapeutics (GBT) (NASDAQ: GBT), based in South SF, is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. We aim to make a significant impact by treating the root cause or making a meaningful difference in the standards of care. Through in-licensing and continued research and development, were committed to Hope+Science+Community. You can view our social community guidelines at http://www.gbt.com/about/social-community-guidelines/keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$25.7M||178||8%||N/A|
|Full Spectrum A...||$6M||42||5%||N/A|
Global Blood Therapeutics News
Global Blood Therapeutics is preparing to “go-it-alone” in commercialization. I provide my three reasons why the company can handle the ...
05, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug ...
After disclosing that the Food and Drug Administration has accepted the company's application to review its lead product candidate for approval ...
Global Blood Therapeutics Funding
|2016-06-21||$115.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2016-06-27||$112.3M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2017-02-23||$125.0M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2017-03-01||$143.8M||Undisclosed||Cantor Fitzgerald & Co||Article|
|2017-12-18||$115.0M||Undisclosed||Cantor Fitzgerald & Co.||Article|
Global Blood Therapeutics Executive Hires
|2014-06-18||Ted W. Love||CEO||Article|
|2014-08-05||Hing Sham||SVP Chemistry||Article|
|2015-04-15||Jung E. Choi||Chief Business/Strategy Officer||Article|
|2016-10-13||Tricia Suvari||Chief Legal Officer||Article|
|2018-03-07||David Johnson||Chief Commercial Officer||Article|
|2018-08-22||Heidi L Wagner||SVP Government Affairs and Policy||Article|